Influenza vaccines: Unmet needs and recent developments

Infection and Chemotherapy

Volumn 45, Issue 4, 2013, Pages 375-386

  Noh, Ji Yun ^a   Kim, Woo Joo ^a,b  

^a Korea University College of Medicine   (South Korea)

^b Transgovernmental Enterprise for Pandemic Influenza   (South Korea)

Author keywords

Human; Influenza; Influenza vaccines; Pandemics

Indexed keywords

HEMAGGLUTININ; INACTIVATED VACCINE; INFLUENZA VACCINE; RECOMBINANT HEMAGGLUTININ INFLUENZA VACCINES; UNCLASSIFIED DRUG;

CULTURE TECHNIQUE; DRUG MEGADOSE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE NEED; HUMAN; INFLUENZA; PANDEMIC INFLUENZA; REVIEW; VACCINATION;

EID: 84893172926     PISSN: 20932340     EISSN: 20926448     Source Type: Journal    
DOI: 10.3947/ic.2013.45.4.375     Document Type: Review

References (98)

1. Hilleman MR. Realities and enigmas of human viral influenza: pathogenesis, epidemiology and control. Vaccine 2002;20:3068-87.
2. McCullers JA, Saito T, Iverson AR. Multiple genotypes of influenza B virus circulated between 1979 and 2003. J Virol 2004;78:12817-28.
3. Smith W, Andrewes CH, Laidlaw PP. A virus obtained from influenza patients. Lancet 1933;2:66-8.
4. Francis T Jr. A new type of virus from epidemic influenza. Science 1940;92:405-8.
5. Cox NJ, Subbarao K. Influenza. Lancet 1999;354:1277-82.
6. Dawood FS, Iuliano AD, Reed C, Meltzer MI, Shay DK, Cheng PY, Bandaranayake D, Breiman RF, Brooks WA, Buchy P, Feikin DR, Fowler KB, Gordon A, Hien NT, Horby P, Huang QS, Katz MA, Krishnan A, Lal R, Montgomery JM, Mølbak K, Pebody R, Presanis AM, Razuri H, Steens A, Tinoco YO, Wallinga J, Yu H, Vong S, Bresee J, Widdowson MA. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infect Dis 2012;12:687-95.
7. Programme WHOGI. Pandemic influenza preparedness and response: a WHO guidance document: World Health Organization; 2009.
8. Team DPIP. UK Influenza pandemic preparedness strategy.2011.
9. Kageyama S. Pandemic influenza: a never-ending story. Yonago Acta Med 2011;54:41-8.
10. Simonsen L, Spreeuwenberg P, Lustig R, Taylor RJ, Fleming DM, Kroneman M, Van Kerkhove MD, Mounts AW, Paget WJ; GLaMOR Collaborating Teams. Global Mortality Estimates for the 2009 Influenza Pandemic from the GLaMOR Project: A Model ing Study. PLoS Med 2013;10:e1001558.
11. WHO. Vaccines: Influenza. Available at: http://www.who. int/biologicals/vaccines/influenza/en/. Accessed 19 November 2013.
12. Terebuh P, Uyeki T, Fukuda K. Impact of influenza on young children and the shaping of United States influenza vaccine policy. Pediatr Infect Dis J 2003;22 (10 Suppl):S231-5.
13. Centers for Disease Control and Prevention (CDC). Prevention and control of seasonal influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices-United States, 2013-2014. MMWR Recomm Rep 2013;62:1-43.
14. Hannoun C. The evolving history of influenza viruses and influenza vaccines. Expert Rev Vaccines 2013;12:1085-94.
15. Partridge J, Kieny MP. Global production capacity of seasonal influenza vaccine in 2011. Vaccine 2013;31:728-31.
16. WHO. WHO recommendations on the composition of influenza virus vaccines. Available at: http://www.who.int/ influenza/vaccines/virus/recommendations/en/. Accessed 19 November 2013.
17. Richard SA, Viboud C, Miller MA. Evaluation of Southern Hemisphere influenza vaccine recommendations. Vaccine 2010;28:2693-9.
18. Influenza research database. World health organization recommendations for composition of influenza vaccines Available at: http://www.fludb.org/brc/vaccineRecommend. do?decorator=influenza. Accessed 16 December 2013.
19. Nichol KL. Efficacy and effectiveness of influenza vaccination. Vaccine 2008;26 (Suppl 4):D17-22.
20. DiazGranados CA, Denis M, Plotkin S. Seasonal influenza vaccine efficacy and its determinants in children and nonelderly adults: a systematic review with meta-analyses of controlled trials. Vaccine 2012;31:49-57.
21. Jefferson TO, Rivetti D, Di Pietrantonj C, Rivetti A, Demicheli V. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2007:CD001269.
22. Edwards KM, Dupont WD, Westrich MK, Plummer WD, Jr., Palmer PS, Wright PF. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J Infect Dis 1994;169:68-76.
23. Choi WS, Noh JY, Seo YB, Baek JH, Lee J, Song JY, Park DW, Lee JS, Cheong HJ, Kim WJ. Case-control study of the effectiveness of the 2010-2011 seasonal influenza vaccine for prevention of laboratory-confirmed influenza virus infection in the Korean adult population. Clin Vaccine Immunol 2013;20:877-81.
24. Beyer WE, McElhaney J, Smith DJ, Monto AS, Nguyen-Van-Tam JS, Osterhaus AD. Cochrane re-arranged: Support for policies to vaccinate elderly people against influenza. Vaccine 2013;31:6030-3.
25. Vu T, Farish S, Jenkins M, Kelly H. A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community. Vaccine 2002;20:1831-6.
26. Nichol KL, Margolis KL, Wuorenma J, Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 1994;331:778-84.
27. Carrat F, Flahault A. Influenza vaccine: the challenge of antigenic drift. Vaccine 2007;25:6852-62.
28. Nordin J, Mullooly J, Poblete S, Strikas R, Petrucci R, Wei F, Rush B, Safirstein B, Wheeler D, Nichol KL. Influenza vaccine effectiveness in preventing hospitalizations and deaths in persons 65 years or older in Minnesota, New York, and Oregon: data from 3 health plans. J Infect Dis 2001;184:665-70.
29. Ambrose CS, Wu X, Jones T, Mallory RM. The role of nasal IgA in children vaccinated with live attenuated influenza vaccine. Vaccine 2012;30:6794-801.
30. Meadows M. Nasal flu vaccine approved. FDA Consum 2003;37:27.
31. Ambrose CS, Levin MJ, Belshe RB. The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults. Influenza Other Respir Viruses 2011;5:67-75.
32. Longini IM, Halloran ME, Nizam A, Wolff M, Mendelman PM, Fast PE, Belshe RB. Estimation of the efficacy of live, attenuated influenza vaccine from a two-year, multi-center vaccine trial: implications for influenza epidemic control. Vaccine 2000;18:1902-9.
33. Belshe RB, Mendelman PM, Treanor J, King J, Gruber WC, Piedra P, Bernstein DI, Hayden FG, Kotloff K, Zangwill K, Iacuzio D, Wolff M. The efficacy of live attenuated, coldadapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med 1998;338:1405-12.
34. Belshe RB, Gruber WC. Prevention of otitis media in children with live attenuated influenza vaccine given intranasally. Pediatr Infect Dis J 2000;19 (5 Suppl):S66-71.
35. Monto AS, Ohmit SE, Petrie JG, Johnson E, Truscon R, Teich E, Rotthoff J, Boulton M, Victor JC. Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med 2009;361:1260-7.
36. Prosser LA, Meltzer MI, Fiore A, Epperson S, Bridges CB, Hinrichsen V, Lieu TA. Effects of adverse events on the projected population benefits and cost-effectiveness of using live attenuated influenza vaccine in children aged 6 months to 4 years. Arch Pediatr Adolesc Med 2011;165:112-8.
37. Reed SG, Orr MT, Fox CB. Key roles of adjuvants in modern vaccines. Nat Med 2013;19:1597-608.
38. Salk JE, Laurent AM, Bailey ML. Direction of research on vaccination against influenza; new studies with immunologic adjuvants. Am J Public Health Nations Health 1951;41:669-77.
39. Salk JE, Laurent AM. The use of adjuvants in studies on influenza immunization. I. Measurements in monkeys of the dimensions of antigenicity of virus-mineral oil emulsions. J Exp Med 1952;95:429-47.
40. Herbert WJ, Selwyn S, Philp JR. Field trials of adjuvant and saline influenza vaccines. Br J Prev Soc Med 1965;19:97-100.
41. Anonymous. Antibody responses and clinical reactions with saline and oil adjuvant influenza virus vaccines. Br Med J 1955;2:1229-32.
42. Stuart-Harris CH. Adjuvant influenza vaccines. Bull World Health Organ 1969;41:617-21.
43. Davis DJ, Philip RN, Bell JA, Vogel JE, Jensen DV. Epidemiologic studies on influenza in familial and general population groups. 1951-1956. III. Laboratory observations. Am J Hyg 1961;73:138-47.
44. Tetsutani K, Ishii KJ. Adjuvants in influenza vaccines. Vaccine 2012;30:7658-61.
45. Principi N, Esposito S. Adjuvanted influenza vaccines. Hum Vaccin Immunother 2012;8:59-66.
46. Lindblad EB. Aluminium compounds for use in vaccines. Immunol Cell Biol 2004;82:497-505.
47. Martin JT. Development of an adjuvant to enhance the immune response to influenza vaccine in the elderly. Biologicals 1997;25:209-13.
48. Tsai TF. Fluad®-MF59®-adjuvanted influenza vaccine in older adults. Infect Chemother 2013;45:159-74.
49. Banzhoff A, Nacci P, Podda A. A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis. Gerontology 2003;49:177-84.
50. Squarcione S, Sgricia S, Biasio LR, Perinetti E. Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects. Vaccine 2003;21:1268-74.
51. Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 2001;19:2673-80.
52. Ansaldi F, Canepa P, Parodi V, Bacilieri S, Orsi A, Compagnino F, Icardi G, Durando P. Adjuvanted seasonal influenza vaccines and perpetual viral metamorphosis: the importance of cross-protection. Vaccine 2009;27:3345-8.
53. Del Giudice G, Hilbert AK, Bugarini R, Minutello A, Popova O, Toneatto D, Schoendorf I, Borkowski A, Rappuoli R, Podda A. An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine. Vaccine 2006;24:3063-5.
54. Ansaldi F, Bacilieri S, Durando P, Sticchi L, Valle L, Montomoli E, Icardi G, Gasparini R, Crovari P. Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses. Vaccine 2008;26:1525-9.
55. Van Buynder PG, Konrad S, Van Buynder JL, Brodkin E, Krajden M, Ramler G, Bigham M. The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly. Vaccine 2013;31:6122-8.
56. Mannino S, Villa M, Apolone G, Weiss NS, Groth N, Aquino I, Boldori L, Caramaschi F, Gattinoni A, Malchiodi G, Rothman KJ. Effectiveness of adjuvanted influenza vaccination in elderly subjects in northern Italy. Am J Epidemiol 2012;176:527-33.
57. Song JY, Cheong HJ, Noh JY, Seo YB, Choi WS, Cho GJ, Hwang TG, Kim WJ. Long-term and cross-reactive immunogenicity of inactivated trivalent influenza vaccine in the elderly: MF59-adjuvanted vaccine versus unadjuvanted vaccine. J Med Virol 2013;85:1591-7.
58. McElhaney JE, Beran J, Devaster JM, Esen M, Launay O, Leroux-Roels G, Ruiz-Palacios GM, van Essen GA, Caplanusi A, Claeys C, Durand C, Duval X, El Idrissi M, Falsey AR, Feldman G, Frey SE, Galtier F, Hwang SJ, Innis BL, Kovac M, Kremsner P, McNeil S, Nowakowski A, Richardus JH, Trofa A, Oostvogels L; Influence65 study group. AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial. Lancet Infect Dis 2013;13:485-96.
59. Koutsonanos DG, Compans RW, Skountzou I. Targeting the skin for microneedle delivery of influenza vaccine. Adv Exp Med Biol 2013;785:121-32.
60. Nicolas JF, Guy B. Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice. Expert Rev Vaccines 2008;7:1201-14.
61. Durando P, Iudici R, Alicino C, Alberti M, de Florentis D, Ansaldi F, Icardi G. Adjuvants and alternative routes of administration towards the development of the ideal influenza vaccine. Hum Vaccin 2011;7 (Suppl):29-40.
62. Belshe RB, Newman FK, Cannon J, Duane C, Treanor J, Van Hoecke C, Howe BJ, Dubin G. Serum antibody responses after intradermal vaccination against influenza. N Engl J Med 2004;351:2286-94.
63. Jo YM, Song JY, Hwang IS, Lee J, Oh SC, Kim JS, Kim SR, Kim WJ, Cheong HJ. Dose sparing strategy with intradermal influenza vaccination in patients with solid cancer. J Med Virol 2009;81:722-7.
64. Beran J, Ambrozaitis A, Laiskonis A, Mickuviene N, Bacart P, Calozet Y, Demanet E, Heijmans S, Van Belle P, Weber F, Salamand C. Intradermal influenza vaccination of healthy adults using a new microinjection system: a 3-year randomised controlled safety and immunogenicity trial. BMC Med 2009;7:13.
65. Arnou R, Icardi G, De Decker M, Ambrozaitis A, Kazek MP, Weber F, Van Damme P. Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study. Vaccine 2009;27:7304-12.
66. Durando P, Alicino C, Alberti M, Sticchi L, Turello V, Marensi L, Caiazzo AL, Panico MG, Giugliano F, Parlato A, Peluso F, Sgricia S, Icardi G; Italian Intradermal Influenza Vaccine Working Group. Acceptance and safety of the intradermal influenza vaccine among the elderly in Italy: an on-field national study. Adv Ther 2012;29:312-26.
67. Marra F, Young F, Richardson K, Marra CA. A meta-analysis of intradermal versus intramuscular influenza vaccines: immunogenicity and adverse events. Influenza Other Respir Viruses 2013;7:584-603.
68. Kis EE, Winter G, Myschik J. Devices for intradermal vaccination. Vaccine 2012;30:523-38.
69. Duggan ST, Plosker GL. Intanza 15 mug intradermal seasonal influenza vaccine in older adults (aged =60 years): profile report. BioDrugs 2010;24:407-9.
70. Moro PL, Harrington T, Shimabukuro T, Cano M, Museru OI, Menschik D, Broder K. Adverse events after Fluzone® Intradermal vaccine reported to the Vaccine Adverse Event Reporting System (VAERS), 2011-2013. Vaccine 2013;31:4984-7.
71. Falsey AR, Treanor JJ, Tornieporth N, Capellan J, Gorse GJ. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standarddose influenza vaccine in adults 65 years of age and older. J Infect Dis 2009;200:172-80.
72. Tsang P, Gorse GJ, Strout CB, Sperling M, Greenberg DP, Ozol-Godfrey A, Diazgranados C, Landolfi V. Immunogenicity and safety of Fluzone® intradermal and high-dose influenza vaccines in older adults ≥65 years of age: A randomized, controlled, phase II trial. Vaccine 2013;pii S0264-410X.
73. McKittrick N, Frank I, Jacobson JM, White CJ, Kim D, Kappes R, DiGiorgio C, Kenney T, Boyer J, Tebas P. Improved immunogenicity with high-dose seasonal influenza vaccine in HIV-infected persons: a single-center, parallel, randomized trial. Ann Intern Med 2013;158:19-26.
74. Sullivan SJ, Jacobson R, Poland GA. Advances in the vaccination of the elderly against influenza: role of a high-dose vaccine. Expert Rev Vaccines 2010;9:1127-33.
75. DiazGranados CA, Dunning AJ, Jordanov E, Landolfi V, Denis M, Talbot HK. High-dose trivalent influenza vaccine compared to standard dose vaccine in elderly adults: safety, immunogenicity and relative efficacy during the 2009-2010 season. Vaccine 2013;31:861-6.
76. Hess RD, Weber F, Watson K, Schmitt S. Regulatory, biosafety and safety challenges for novel cells as substrates for human vaccines. Vaccine 2012;30:2715-27.
77. Doroshenko A, Halperin SA. Trivalent MDCK cell culturederived influenza vaccine Optaflu® (Novartis Vaccines). Expert Rev Vaccines 2009;8:679-88.
78. Reynales H, Astudillo P, de Vallière S, Hatz C, Schlagenhauf P, Rath B, Velentgas P, Fariña A, Sales-Carmona V, Groth N. A prospective observational safety study on MF59® adjuvanted cell culture-derived vaccine, Celtura® during the A/H1N1 (2009) influenza pandemic. Vaccine 2012;30:6436-43.
79. Barrett PN, Berezuk G, Fritsch S, Aichinger G, Hart MK, El-Amin W, Kistner O, Ehrlich HJ. Efficacy, safety, and immu nogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2011;377:751-9.
80. Chan CY, Tambyah PA. Preflucel®: a Vero-cell culture-derived trivalent influenza vaccine. Expert Rev Vaccines 2012;11:759-73.
81. Vinnemeier CD, Fischer-Herr J, Meyer S, Liebig K, Theeß W, Burchard GD, Cramer JP. Immunogenicity and safety of an inactivated 2012/2013 trivalent influenza vaccine produced in mammalian cell culture (Optaflu®): An open label, uncontrolled study. Hum Vaccin Immunother 2013 [In press].
82. Frey S, Vesikari T, Szymczakiewicz-Multanowska A, Lattanzi M, Izu A, Groth N, Holmes S. Clinical efficacy of cell culture-derived and egg-derived inactivated subunit influenza vaccines in heal thy adul ts. Clin Infect Dis 2010;51:997-1004.
83. Belshe RB. The need for quadrivalent vaccine against seasonal influenza. Vaccine 2010;28 (Suppl 4):D45-53.
84. Ambrose CS, Levin MJ. The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunother 2012;8:81-8.
85. Kieninger D, Sheldon E, Lin WY, Yu CJ, Bayas JM, Gabor JJ, Esen M, Fernandez Roure JL, Narejos Perez S, Alvarez Sanchez C, Feng Y, Claeys C, Peeters M, Innis BL, Jain V. Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged =18 years. BMC Infect Dis 2013;13:343.
86. McKeage K. Inactivated quadrivalent split-virus seasonal influenza vaccine (Fluarix® quadrivalent): a review of its use in the prevention of disease caused by influenza A and B. Drugs 2013;73:1587-94.
87. Pépin S, Donazzolo Y, Jambrecina A, Salamand C, Saville M. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults. Vaccine 2013;31:5572-8.
88. Goldenberg MM. Pharmaceutical approval update. P T 2013;38:150-2.
89. Lambert LC, Fauci AS. Influenza vaccines for the future. N Engl J Med 2010;363:2036-44.
90. Yang LP. Recombinant trivalent influenza vaccine (Flublok ®): a review of its use in the prevention of seasonal influenza in adults. Drugs 2013;73:1357-66.
91. Treanor JJ, El Sahly H, King J, Graham I, Izikson R, Kohberger R, Patriarca P, Cox M. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (Flu-Blok®) against influenza in healthy adults: a randomized, placebo-controlled trial. Vaccine 2011;29:7733-9.
92. Dormitzer PR, Tsai TF, Del Giudice G. New technologies for influenza vaccines. Hum Vaccin Immunother 2012;8:45-58.
93. Ogunremi O, Pasick J, Kobinger GP, Hannaman D, Berhane Y, Clavijo A, van Drunen Littel-van den Hurk S. A single electroporation delivery of a DNA vaccine containing the hemagglutinin gene of Asian H5N1 avian influenza virus generated a protective antibody response in chickens against a North American virus strain. Clin Vaccine Immunol 2013;20:491-500.
94. Li J, Jiang Y, Zhao S, Chang X, Liu J, Zeng X, Li Y, Chen H. Protective efficacy of an H5N1 DNA vaccine against challenge with a lethal H5N1 virus in quail. Avian Dis 2012;56 (4 Suppl):937-9.
95. Ellebedy AH, Webby RJ. Influenza vaccines. Vaccine 2009;27 (Suppl 4):D65-8.
96. Shaw A. New technologies for new influenza vaccines. Vaccine 2012;30:4927-33.
97. Pica N, Palese P. Toward a universal influenza virus vaccine: prospects and challenges. Annu Rev Med 2013;64: 189-202.
98. Goodman AG, Heinen PP, Guerra S, Vijayan A, Sorzano CO, Gomez CE, Esteban M. A human multi-epitope recombinant vaccinia virus as a universal T cell vaccine candidate against influenza virus. PLoS One 2011;6:e25938.